News

Wall Street just freaked out about a potential hiccup to a revolutionary gene editing technology — but it’s not as bad as it seems

Companies that develop medications using the revolutionary gene-editing technology CRISPR took a hit on Monday after a study found some concerns about an immune response to the technology. CRISPR Therapeutics dropped sharply on Monday before rebounding, ending the day down 2.8%. Intellia Therapeutics and Editas Medicine both fell by about […]
Wall Street just freaked out about a potential hiccup to a revolutionary gene editing technology  —  but it’s not as bad as it seems